Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Identifieur interne : 002844 ( PubMed/Curation ); précédent : 002843; suivant : 002845Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Auteurs : Fred Saad [Canada] ; Neal Shore [États-Unis] ; Hendrik Van Poppel [Belgique] ; Dana E. Rathkopf [États-Unis] ; Matthew R. Smith [États-Unis] ; Johann S. De Bono [Royaume-Uni] ; Christopher J. Logothetis [États-Unis] ; Paul De Souza [Australie] ; Karim Fizazi [France] ; Peter F A. Mulders [Pays-Bas] ; Paul Mainwaring [Australie] ; John D. Hainsworth [États-Unis] ; Tomasz M. Beer [États-Unis] ; Scott North [Canada] ; Yves Fradet [Canada] ; Thomas A. Griffin [États-Unis] ; Peter De Porre [Belgique] ; Anil Londhe [États-Unis] ; Thian Kheoh [États-Unis] ; Eric J. Small [États-Unis] ; Howard I. Scher [États-Unis] ; Arturo Molina [États-Unis] ; Charles J. Ryan [États-Unis]Source :
- European urology [ 1873-7560 ] ; 2015.
Descripteurs français
- KwdFr :
- Acétate d'abiratérone (effets indésirables), Acétate d'abiratérone (usage thérapeutique), Adulte d'âge moyen, Agents de maintien de la densité osseuse (effets indésirables), Agents de maintien de la densité osseuse (usage thérapeutique), Antinéoplasiques hormonaux (effets indésirables), Antinéoplasiques hormonaux (usage thérapeutique), Essais cliniques de phase III comme sujet, Essais contrôlés randomisés comme sujet, Estimation de Kaplan-Meier, Facteurs de risque, Facteurs temps, Humains, Inhibiteurs de la synthèse des stéroïdes (effets indésirables), Inhibiteurs de la synthèse des stéroïdes (usage thérapeutique), Modèles de hasards proportionnels, Mâle, Odds ratio, Ostéonécrose de la mâchoire associée aux biphosphonates (étiologie), Prednisone (usage thérapeutique), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Survie sans rechute, Tumeurs osseuses (mortalité), Tumeurs osseuses (secondaire), Tumeurs osseuses (traitement médicamenteux), Tumeurs prostatiques résistantes à la castration (anatomopathologie), Tumeurs prostatiques résistantes à la castration (mortalité), Tumeurs prostatiques résistantes à la castration (traitement médicamenteux), Études multicentriques comme sujet, Études rétrospectives.
- MESH :
- anatomopathologie : Tumeurs prostatiques résistantes à la castration.
- effets indésirables : Acétate d'abiratérone, Agents de maintien de la densité osseuse, Antinéoplasiques hormonaux, Inhibiteurs de la synthèse des stéroïdes, Protocoles de polychimiothérapie antinéoplasique.
- mortalité : Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- secondaire : Tumeurs osseuses.
- traitement médicamenteux : Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- usage thérapeutique : Acétate d'abiratérone, Agents de maintien de la densité osseuse, Antinéoplasiques hormonaux, Inhibiteurs de la synthèse des stéroïdes, Prednisone, Protocoles de polychimiothérapie antinéoplasique.
- étiologie : Ostéonécrose de la mâchoire associée aux biphosphonates.
- Adulte d'âge moyen, Essais cliniques de phase III comme sujet, Essais contrôlés randomisés comme sujet, Estimation de Kaplan-Meier, Facteurs de risque, Facteurs temps, Humains, Modèles de hasards proportionnels, Mâle, Odds ratio, Résultat thérapeutique, Sujet âgé, Survie sans rechute, Études multicentriques comme sujet, Études rétrospectives.
English descriptors
- KwdEn :
- Abiraterone Acetate (adverse effects), Abiraterone Acetate (therapeutic use), Aged, Antineoplastic Agents, Hormonal (adverse effects), Antineoplastic Agents, Hormonal (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology), Bone Density Conservation Agents (adverse effects), Bone Density Conservation Agents (therapeutic use), Bone Neoplasms (drug therapy), Bone Neoplasms (mortality), Bone Neoplasms (secondary), Clinical Trials, Phase III as Topic, Disease-Free Survival, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multicenter Studies as Topic, Odds Ratio, Prednisone (therapeutic use), Proportional Hazards Models, Prostatic Neoplasms, Castration-Resistant (drug therapy), Prostatic Neoplasms, Castration-Resistant (mortality), Prostatic Neoplasms, Castration-Resistant (pathology), Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Steroid Synthesis Inhibitors (adverse effects), Steroid Synthesis Inhibitors (therapeutic use), Time Factors, Treatment Outcome.
- MESH :
- chemical , adverse effects : Abiraterone Acetate, Antineoplastic Agents, Hormonal, Bone Density Conservation Agents, Steroid Synthesis Inhibitors.
- chemical , therapeutic use : Abiraterone Acetate, Antineoplastic Agents, Hormonal, Bone Density Conservation Agents, Prednisone, Steroid Synthesis Inhibitors.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- etiology : Bisphosphonate-Associated Osteonecrosis of the Jaw.
- mortality : Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- pathology : Prostatic Neoplasms, Castration-Resistant.
- secondary : Bone Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Clinical Trials, Phase III as Topic, Disease-Free Survival, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multicenter Studies as Topic, Odds Ratio, Proportional Hazards Models, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome.
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.
DOI: 10.1016/j.eururo.2015.04.032
PubMed: 25985882
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002913
Links to Exploration step
pubmed:25985882Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.</title>
<author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Montréal, Montréal, Québec, Canada. Electronic address: fredsaad@videotron.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Montréal, Montréal, Québec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shore, Neal" sort="Shore, Neal" uniqKey="Shore N" first="Neal" last="Shore">Neal Shore</name>
<affiliation wicri:level="1"><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Van Poppel, Hendrik" sort="Van Poppel, Hendrik" uniqKey="Van Poppel H" first="Hendrik" last="Van Poppel">Hendrik Van Poppel</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospital Leuven, Leuven, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospital Leuven, Leuven</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name>
<affiliation wicri:level="1"><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name>
<affiliation wicri:level="1"><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Harvard Medical School and Massachusetts General Hospital, Boston, MA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Research and Royal Marsden Hospital, Sutton</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name>
<affiliation wicri:level="1"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Western Sydney School of Medicine, Ingham Institute, Liverpool</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name>
<affiliation wicri:level="1"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name>
<affiliation wicri:level="1"><nlm:affiliation>Hematology and Oncology Clinics of Australia, Brisbane, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Hematology and Oncology Clinics of Australia, Brisbane</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hainsworth, John D" sort="Hainsworth, John D" uniqKey="Hainsworth J" first="John D" last="Hainsworth">John D. Hainsworth</name>
<affiliation wicri:level="1"><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sarah Cannon Research Institute, Nashville, TN</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Beer, Tomasz M" sort="Beer, Tomasz M" uniqKey="Beer T" first="Tomasz M" last="Beer">Tomasz M. Beer</name>
<affiliation wicri:level="1"><nlm:affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Oregon Health & Science University Knight Cancer Institute, Portland, OR</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="North, Scott" sort="North, Scott" uniqKey="North S" first="Scott" last="North">Scott North</name>
<affiliation wicri:level="1"><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Cross Cancer Institute, Edmonton, Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fradet, Yves" sort="Fradet, Yves" uniqKey="Fradet Y" first="Yves" last="Fradet">Yves Fradet</name>
<affiliation wicri:level="1"><nlm:affiliation>Laval University, Québec City, Québec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Laval University, Québec City, Québec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A" last="Griffin">Thomas A. Griffin</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Londhe, Anil" sort="Londhe, Anil" uniqKey="Londhe A" first="Anil" last="Londhe">Anil Londhe</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, Raritan, NJ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, San Diego, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, San Diego, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name>
<affiliation wicri:level="1"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name>
<affiliation wicri:level="1"><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, Menlo Park, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name>
<affiliation wicri:level="1"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25985882</idno>
<idno type="pmid">25985882</idno>
<idno type="doi">10.1016/j.eururo.2015.04.032</idno>
<idno type="wicri:Area/PubMed/Corpus">002913</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002913</idno>
<idno type="wicri:Area/PubMed/Curation">002844</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002844</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.</title>
<author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Montréal, Montréal, Québec, Canada. Electronic address: fredsaad@videotron.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Montréal, Montréal, Québec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shore, Neal" sort="Shore, Neal" uniqKey="Shore N" first="Neal" last="Shore">Neal Shore</name>
<affiliation wicri:level="1"><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Van Poppel, Hendrik" sort="Van Poppel, Hendrik" uniqKey="Van Poppel H" first="Hendrik" last="Van Poppel">Hendrik Van Poppel</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospital Leuven, Leuven, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospital Leuven, Leuven</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name>
<affiliation wicri:level="1"><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name>
<affiliation wicri:level="1"><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Harvard Medical School and Massachusetts General Hospital, Boston, MA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Research and Royal Marsden Hospital, Sutton</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name>
<affiliation wicri:level="1"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Western Sydney School of Medicine, Ingham Institute, Liverpool</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name>
<affiliation wicri:level="1"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name>
<affiliation wicri:level="1"><nlm:affiliation>Hematology and Oncology Clinics of Australia, Brisbane, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Hematology and Oncology Clinics of Australia, Brisbane</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hainsworth, John D" sort="Hainsworth, John D" uniqKey="Hainsworth J" first="John D" last="Hainsworth">John D. Hainsworth</name>
<affiliation wicri:level="1"><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sarah Cannon Research Institute, Nashville, TN</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Beer, Tomasz M" sort="Beer, Tomasz M" uniqKey="Beer T" first="Tomasz M" last="Beer">Tomasz M. Beer</name>
<affiliation wicri:level="1"><nlm:affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Oregon Health & Science University Knight Cancer Institute, Portland, OR</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="North, Scott" sort="North, Scott" uniqKey="North S" first="Scott" last="North">Scott North</name>
<affiliation wicri:level="1"><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Cross Cancer Institute, Edmonton, Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fradet, Yves" sort="Fradet, Yves" uniqKey="Fradet Y" first="Yves" last="Fradet">Yves Fradet</name>
<affiliation wicri:level="1"><nlm:affiliation>Laval University, Québec City, Québec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Laval University, Québec City, Québec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A" last="Griffin">Thomas A. Griffin</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Londhe, Anil" sort="Londhe, Anil" uniqKey="Londhe A" first="Anil" last="Londhe">Anil Londhe</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, Raritan, NJ</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, San Diego, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, San Diego, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name>
<affiliation wicri:level="1"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name>
<affiliation wicri:level="1"><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name>
<affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, Menlo Park, CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name>
<affiliation wicri:level="1"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">European urology</title>
<idno type="eISSN">1873-7560</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abiraterone Acetate (adverse effects)</term>
<term>Abiraterone Acetate (therapeutic use)</term>
<term>Aged</term>
<term>Antineoplastic Agents, Hormonal (adverse effects)</term>
<term>Antineoplastic Agents, Hormonal (therapeutic use)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology)</term>
<term>Bone Density Conservation Agents (adverse effects)</term>
<term>Bone Density Conservation Agents (therapeutic use)</term>
<term>Bone Neoplasms (drug therapy)</term>
<term>Bone Neoplasms (mortality)</term>
<term>Bone Neoplasms (secondary)</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Disease-Free Survival</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multicenter Studies as Topic</term>
<term>Odds Ratio</term>
<term>Prednisone (therapeutic use)</term>
<term>Proportional Hazards Models</term>
<term>Prostatic Neoplasms, Castration-Resistant (drug therapy)</term>
<term>Prostatic Neoplasms, Castration-Resistant (mortality)</term>
<term>Prostatic Neoplasms, Castration-Resistant (pathology)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Steroid Synthesis Inhibitors (adverse effects)</term>
<term>Steroid Synthesis Inhibitors (therapeutic use)</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acétate d'abiratérone (effets indésirables)</term>
<term>Acétate d'abiratérone (usage thérapeutique)</term>
<term>Adulte d'âge moyen</term>
<term>Agents de maintien de la densité osseuse (effets indésirables)</term>
<term>Agents de maintien de la densité osseuse (usage thérapeutique)</term>
<term>Antinéoplasiques hormonaux (effets indésirables)</term>
<term>Antinéoplasiques hormonaux (usage thérapeutique)</term>
<term>Essais cliniques de phase III comme sujet</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs de risque</term>
<term>Facteurs temps</term>
<term>Humains</term>
<term>Inhibiteurs de la synthèse des stéroïdes (effets indésirables)</term>
<term>Inhibiteurs de la synthèse des stéroïdes (usage thérapeutique)</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Odds ratio</term>
<term>Ostéonécrose de la mâchoire associée aux biphosphonates (étiologie)</term>
<term>Prednisone (usage thérapeutique)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Survie sans rechute</term>
<term>Tumeurs osseuses (mortalité)</term>
<term>Tumeurs osseuses (secondaire)</term>
<term>Tumeurs osseuses (traitement médicamenteux)</term>
<term>Tumeurs prostatiques résistantes à la castration (anatomopathologie)</term>
<term>Tumeurs prostatiques résistantes à la castration (mortalité)</term>
<term>Tumeurs prostatiques résistantes à la castration (traitement médicamenteux)</term>
<term>Études multicentriques comme sujet</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Abiraterone Acetate</term>
<term>Antineoplastic Agents, Hormonal</term>
<term>Bone Density Conservation Agents</term>
<term>Steroid Synthesis Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abiraterone Acetate</term>
<term>Antineoplastic Agents, Hormonal</term>
<term>Bone Density Conservation Agents</term>
<term>Prednisone</term>
<term>Steroid Synthesis Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs prostatiques résistantes à la castration</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term>
<term>Prostatic Neoplasms, Castration-Resistant</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Acétate d'abiratérone</term>
<term>Agents de maintien de la densité osseuse</term>
<term>Antinéoplasiques hormonaux</term>
<term>Inhibiteurs de la synthèse des stéroïdes</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Bisphosphonate-Associated Osteonecrosis of the Jaw</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Bone Neoplasms</term>
<term>Prostatic Neoplasms, Castration-Resistant</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs osseuses</term>
<term>Tumeurs prostatiques résistantes à la castration</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostatic Neoplasms, Castration-Resistant</term>
</keywords>
<keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term>
</keywords>
<keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs osseuses</term>
<term>Tumeurs prostatiques résistantes à la castration</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acétate d'abiratérone</term>
<term>Agents de maintien de la densité osseuse</term>
<term>Antinéoplasiques hormonaux</term>
<term>Inhibiteurs de la synthèse des stéroïdes</term>
<term>Prednisone</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Ostéonécrose de la mâchoire associée aux biphosphonates</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Disease-Free Survival</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multicenter Studies as Topic</term>
<term>Odds Ratio</term>
<term>Proportional Hazards Models</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Essais cliniques de phase III comme sujet</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs de risque</term>
<term>Facteurs temps</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Odds ratio</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Survie sans rechute</term>
<term>Études multicentriques comme sujet</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25985882</PMID>
<DateCreated><Year>2015</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>06</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>68</Volume>
<Issue>4</Issue>
<PubDate><Year>2015</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>European urology</Title>
<ISOAbbreviation>Eur. Urol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.</ArticleTitle>
<Pagination><MedlinePgn>570-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2015.04.032</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0302-2838(15)00374-7</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Investigation of outcomes for concomitant BTT in a post hoc analysis of the COU-AA-302 trial, which demonstrated an overall clinical benefit of abiraterone acetate (AA) plus prednisone over placebo plus prednisone in asymptomatic or mildly symptomatic chemotherapy-naïve mCRPC patients.</AbstractText>
<AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This report describes the third interim analysis (prespecified at 55% overall survival [OS] events) for the COU-AA-302 trial.</AbstractText>
<AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were grouped by concomitant BTT use or no BTT use.</AbstractText>
<AbstractText Label="OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS" NlmCategory="METHODS">Radiographic progression-free survival and OS were coprimary end points. This report describes the third interim analysis (prespecified at 55% OS events) and involves patients treated with or without concomitant BTT during the COU-AA-302 study. Median follow-up for OS was 27.1 mo. Median time-to-event variables with 95% confidence intervals (CIs) were estimated using the Kaplan-Meier method. Adjusted hazard ratios (HRs), 95% CIs, and p values for concomitant BTT versus no BTT were obtained via Cox models.</AbstractText>
<AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">While the post hoc nature of the analysis is a limitation, superiority of AA and prednisone versus prednisone alone was demonstrated for clinical outcomes with or without BTT use. Compared with no BTT use, concomitant BTT significantly improved OS (HR 0.75; p=0.01) and increased the time to ECOG deterioration (HR 0.75; p<0.001) and time to opiate use for cancer-related pain (HR 0.80; p=0.036). The safety profile of concomitant BTT with AA was similar to that reported for AA in the overall intent-to-treat population. Osteonecrosis of the jaw (all grade 1/2) with concomitant BTT use was reported in <3% of patients.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AA with concomitant BTT was safe and well tolerated in men with chemotherapy-naïve mCRPC. The benefits of AA on clinical outcomes were increased with concomitant BTT.</AbstractText>
<AbstractText Label="PATIENT SUMMARY" NlmCategory="RESULTS">Treatment of advanced prostate cancer often includes bone-targeted therapy. This post hoc analysis showed that in patients with advanced prostate cancer who were treated with abiraterone acetate and prednisone in combination with bone-targeted therapy, there was a continued trend in prolongation of life when compared with patients treated with prednisone alone.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT00887198.</AbstractText>
<CopyrightInformation>Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saad</LastName>
<ForeName>Fred</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>University of Montréal, Montréal, Québec, Canada. Electronic address: fredsaad@videotron.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shore</LastName>
<ForeName>Neal</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Van Poppel</LastName>
<ForeName>Hendrik</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>University Hospital Leuven, Leuven, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rathkopf</LastName>
<ForeName>Dana E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>Matthew R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Bono</LastName>
<ForeName>Johann S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo><Affiliation>Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Logothetis</LastName>
<ForeName>Christopher J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Souza</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fizazi</LastName>
<ForeName>Karim</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mulders</LastName>
<ForeName>Peter F A</ForeName>
<Initials>PF</Initials>
<AffiliationInfo><Affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mainwaring</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Hematology and Oncology Clinics of Australia, Brisbane, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hainsworth</LastName>
<ForeName>John D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo><Affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Beer</LastName>
<ForeName>Tomasz M</ForeName>
<Initials>TM</Initials>
<AffiliationInfo><Affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>North</LastName>
<ForeName>Scott</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fradet</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Laval University, Québec City, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Griffin</LastName>
<ForeName>Thomas A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Los Angeles, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Porre</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Beerse, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Londhe</LastName>
<ForeName>Anil</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Raritan, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kheoh</LastName>
<ForeName>Thian</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, San Diego, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Small</LastName>
<ForeName>Eric J</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Scher</LastName>
<ForeName>Howard I</ForeName>
<Initials>HI</Initials>
<AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molina</LastName>
<ForeName>Arturo</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Menlo Park, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ryan</LastName>
<ForeName>Charles J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00887198</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>05</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Eur Urol</MedlineTA>
<NlmUniqueID>7512719</NlmUniqueID>
<ISSNLinking>0302-2838</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065088">Steroid Synthesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EM5OCB9YJ6</RegistryNumber>
<NameOfSubstance UI="D000069501">Abiraterone Acetate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VB0R961HZT</RegistryNumber>
<NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2015 Oct;68(4):578-80</RefSource>
<PMID Version="1">26116295</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2008 Jul 1;113(1):193-201</RefSource>
<PMID Version="1">18459173</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Nov;14(12):1193-9</RefSource>
<PMID Version="1">24075621</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Support Care Cancer. 2008 Aug;16(8):879-89</RefSource>
<PMID Version="1">18392862</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Genitourin Cancer. 2007 Sep;5(6):390-6</RefSource>
<PMID Version="1">17956712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2004 Mar 1;100(5):892-9</RefSource>
<PMID Version="1">14983482</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Genitourin Cancer. 2013 Mar;11(1):20-6</RefSource>
<PMID Version="1">23021204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Mar 1;26(7):1148-59</RefSource>
<PMID Version="1">18309951</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2013 May;39(3):275-89</RefSource>
<PMID Version="1">23107383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Urol. 2013 Sep;10(9):522-8</RefSource>
<PMID Version="1">23797341</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Opin Support Palliat Care. 2012 Sep;6(3):299-303</RefSource>
<PMID Version="1">22871982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Jan 7;379(9810):39-46</RefSource>
<PMID Version="1">22093187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Jun 15;17(12):3876-83</RefSource>
<PMID Version="1">21680543</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2001 Sep 27;345(13):948-55</RefSource>
<PMID Version="1">11575286</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68</RefSource>
<PMID Version="1">12359855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 2007 May;16(4):571-5</RefSource>
<PMID Version="1">17294287</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2011 Mar;185(3):787-94</RefSource>
<PMID Version="1">21239012</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Oct;13(10):983-92</RefSource>
<PMID Version="1">22995653</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2014 Nov;66(5):815-25</RefSource>
<PMID Version="1">24647231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</RefSource>
<PMID Version="1">22237781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 May 26;364(21):1995-2005</RefSource>
<PMID Version="1">21612468</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hum Pathol. 2000 May;31(5):578-83</RefSource>
<PMID Version="1">10836297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2013 Mar 1;132(5):1133-45</RefSource>
<PMID Version="1">22752881</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Prostate Cancer. 2013;2013:210686</RefSource>
<PMID Version="1">24069538</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jan 10;368(2):138-48</RefSource>
<PMID Version="1">23228172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Dec;13(12 ):1210-7</RefSource>
<PMID Version="1">23142059</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2011 Mar 5;377(9768):813-22</RefSource>
<PMID Version="1">21353695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2006 Jan;175(1):27-34</RefSource>
<PMID Version="1">16406864</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2012 Oct 28;323(2):135-46</RefSource>
<PMID Version="1">22521546</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000069501" MajorTopicYN="N">Abiraterone Acetate</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059266" MajorTopicYN="N">Bisphosphonate-Associated Osteonecrosis of the Jaw</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065088" MajorTopicYN="N">Steroid Synthesis Inhibitors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abiraterone acetate</Keyword>
<Keyword MajorTopicYN="N">Bone-targeted therapy</Keyword>
<Keyword MajorTopicYN="N">Chemotherapy-naïve</Keyword>
<Keyword MajorTopicYN="N">Metastatic castration-resistant prostate cancer</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>01</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>04</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>6</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25985882</ArticleId>
<ArticleId IdType="pmc">PMC5056561</ArticleId>
<ArticleId IdType="pii">S0302-2838(15)00374-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.eururo.2015.04.032</ArticleId>
<ArticleId IdType="mid">NIHMS810853</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002844 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002844 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:25985882 |texte= Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25985882" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |